Victoria Chang, MD | |
3880 Tamiami Trl N, Naples, FL 34103-3504 | |
(239) 659-3944 | |
Not Available |
Full Name | Victoria Chang |
---|---|
Gender | Female |
Speciality | Ophthalmology |
Experience | 14 Years |
Location | 3880 Tamiami Trl N, Naples, Florida |
Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
Identifier | Type | State | Issuer |
---|---|---|---|
1043520109 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
207W00000X | Ophthalmology | 258798 (Massachusetts) | Secondary |
207W00000X | Ophthalmology | 123061 (Florida) | Primary |
Group Practice Name | Group PECOS PAC ID | No. of Members |
---|---|---|
University Of Miami | 3274795109 | 1781 |
News Archive
Intellikine, Inc., a company focused on the discovery and development of innovative, small molecule drugs targeting the PI3K/mTOR pathway, announced today that it has earned $4 million in milestone payments upon the initiation of two Phase 1 clinical trials of IPI-145.
Kaiser Health News provides a fresh take on health policy developments with "DeLoreain't?" by Milt Priggee.
X-linked methyl-CpG binding protein 2 plays important role in the regulation of neuronal development, proliferation and maturation, and synaptic regeneration and apoptosis.
Can-Fite BioPharma Ltd., a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory and cancer diseases, announced today that it executed confidentiality agreements with 10 established pharmaceutical and biotechnology companies with respect to potential negotiations for the commercialization of CF101 for the treatment of autoimmune inflammatory indications.
› Verified 4 days ago
Entity Name | University Of Miami |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1013967827 PECOS PAC ID: 3274795109 Enrollment ID: O20200406001006 |
News Archive
Intellikine, Inc., a company focused on the discovery and development of innovative, small molecule drugs targeting the PI3K/mTOR pathway, announced today that it has earned $4 million in milestone payments upon the initiation of two Phase 1 clinical trials of IPI-145.
Kaiser Health News provides a fresh take on health policy developments with "DeLoreain't?" by Milt Priggee.
X-linked methyl-CpG binding protein 2 plays important role in the regulation of neuronal development, proliferation and maturation, and synaptic regeneration and apoptosis.
Can-Fite BioPharma Ltd., a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory and cancer diseases, announced today that it executed confidentiality agreements with 10 established pharmaceutical and biotechnology companies with respect to potential negotiations for the commercialization of CF101 for the treatment of autoimmune inflammatory indications.
› Verified 4 days ago
Mailing Address | Practice Location Address |
---|---|
Victoria Chang, MD 243 Charles St, Meei/department Of Ophthalmology, Boston, MA 02114-3002 Ph: () - | Victoria Chang, MD 3880 Tamiami Trl N, Naples, FL 34103-3504 Ph: (239) 659-3944 |
News Archive
Intellikine, Inc., a company focused on the discovery and development of innovative, small molecule drugs targeting the PI3K/mTOR pathway, announced today that it has earned $4 million in milestone payments upon the initiation of two Phase 1 clinical trials of IPI-145.
Kaiser Health News provides a fresh take on health policy developments with "DeLoreain't?" by Milt Priggee.
X-linked methyl-CpG binding protein 2 plays important role in the regulation of neuronal development, proliferation and maturation, and synaptic regeneration and apoptosis.
Can-Fite BioPharma Ltd., a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory and cancer diseases, announced today that it executed confidentiality agreements with 10 established pharmaceutical and biotechnology companies with respect to potential negotiations for the commercialization of CF101 for the treatment of autoimmune inflammatory indications.
› Verified 4 days ago
Dr. James Sheridan Kelley, MD Ophthalmology Medicare: Not Enrolled in Medicare Practice Location: 2355 Stanford Ct Unit 701, Naples, FL 34112 Phone: 239-566-7425 Fax: 239-593-3430 | |
Dr. Howard Lee Freedman, M.D. Ophthalmology Medicare: Not Enrolled in Medicare Practice Location: 2171 Pine Ridge Rd, Suite F, Naples, FL 34109 Phone: 239-566-7425 Fax: 239-593-3430 | |
Julia A Carter, MD Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 700 Neapolitan Way, Naples, FL 34103 Phone: 239-261-8383 Fax: 239-261-8443 | |
Dr. Lynn Kepple Byerly, M.D. Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 661 Goodlette Rd N, Suite 105, Naples, FL 34102 Phone: 239-262-6288 Fax: 239-262-5434 | |
Dr. George Briton Fisher Iii, D.O. Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 875 105th Ave North, Naples, FL 34108 Phone: 239-431-7070 Fax: 239-431-7075 | |
Dr. Jon R Berlie, M.D. Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 700 Neapolitan Way, Naples, FL 34103 Phone: 239-261-8383 Fax: 239-261-8443 |